Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telomir-Ag2
- Development stage
- Preclinical
- Lead developer
- Telomir Pharmaceuticals
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Administration
- Topical
01
Overview
Telomir-Ag2 is a novel, stabilized Silver(II) complex developed by Telomir Pharmaceuticals for the treatment of bacterial infections, including those caused by drug-resistant pathogens. Leveraging the proprietary Telomir-1 chelation platform, this compound overcomes the historical instability of Silver(II), enabling its use as a broad-spectrum antimicrobial agent. In preclinical studies, Telomir-Ag2 demonstrated potent activity against a range of bacteria—including *Escherichia coli*, *Pseudomonas aeruginosa*, *Enterococcus faecalis*, and both methicillin-resistant and aminoglycoside-resistant *Staphylococcus aureus* (MARSA). The compound outperformed Silver(I) analogs in minimum inhibitory concentration assays and does not contain sulfa-based compounds, reducing allergic and cytotoxic risks. Its mechanism involves multiple antibacterial actions typical of silver ions—disrupting membranes, binding proteins/DNA, and generating reactive oxygen species—with enhanced oxidative capacity due to its Silver(II) state. The primary development focus is on topical applications for burn wounds, surgical infection prevention, and hospital-acquired infection control[1][2][6].
- Brand names
- Telomir-Ag2Telomir-Ag-2Telomir-Ag 2
- Other names
- Telomir-Ag2Telomir-Ag-2Telomir-Ag 2
02
Targets
Neuraminidase
Beyond the preview
Go deeper on Telomir-Ag2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telomir-Ag2.